TCRT · NASDAQ
Alaunos Therapeutics, Inc.
$2.00 -0.12 (-5.66%)
Company overview
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. The company develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers, along with hunTR, a human neoantigen T-cell receptor platform, and mbIL-15 to treat solid tumors. Alaunos Therapeutics has a license agreement with PGEN Therapeutics, Inc., a research and development agreement with The University of Texas MD Anderson Cancer Center, and a patent license and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $5.9M
- Employees
- 1
- Headquarters
- Houston, TX
- Website
- alaunos.com
- CEO
- Holger Weis
- Listed
- August 24, 2005
- P/E
- -0.92
- Dividend yield
- 0.00%
Company financials
- Revenue
- $3,000
- Gross profit
- -$190,000
- Operating income
- -$4.1M
- EBITDA
- -$4.1M
- Net income
- -$4.1M
- EPS
- -$2.17
- Total assets
- $1.9M
- Total debt
- $0.00
- Gross margin
- -6,333.33%
- Net margin
- -136,966.67%
- Earnings yield
- -108.50%
TCRT
1D
NASDAQ
O2.28H2.28L2.02C2.12-0.16 (-7.02%)Vol113.15K